Telix Pharmaceuticals Signs MOU with United Imaging for Strategic Collaboration
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Telix Pharmaceuticals announced the signing of a memorandum of understanding, or MOU, to evaluate a strategic research collaboration in the United States focused on advancing integrated theranostics solutions. The companies will evaluate the combination of United Imaging's scanner platforms, software, connectivity and AI capabilities with Telix's molecular imaging portfolio and validated clinical protocols. The collaboration will explore how a unified approach can drive theranostic workflow efficiencies and standardization. The collaboration will initially focus on TLX101-Px in the U.S, with potential expansion into additional markets, and other Telix products and product candidates, subject to mutual agreement. Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TLX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Telix Pharmaceuticals Aligns with FDA to Advance Clinical Trial
- Clinical Trial Advancement: Telix Pharmaceuticals announced alignment with the FDA, allowing its TLX591-Tx to progress to Phase 2 of the ProstACT global trial for metastatic castration-resistant prostate cancer, marking a significant milestone in drug development.
- Trial Design Confirmation: The FDA confirmed that the safety data from Part 1 of the ProstACT trial is sufficient to support the progression of Part 2, while also aligning with Telix on the clinical trial protocol, statistical analysis plan, and ongoing safety monitoring, ensuring scientific rigor and safety.
- Revenue Growth Expectations: Telix expects Q1 2026 revenue to reach $230 million, a 24% increase year-over-year, and projects full-year revenue between $950 million and $970 million, indicating strong growth potential in the biopharmaceutical sector.
- Stock Performance Review: TLX shares have traded between $6.28 and $16.98 over the past year, closing at $11.84, up 2.69% from the previous day, reflecting market optimism regarding the company's future developments.
See More
Telix and FDA Align on Advancing ProstACT Study into Part 2
- FDA Approval Progress: Telix successfully held a Type B meeting with the FDA, which confirmed that the safety data from Part 1 is sufficient to support the advancement of the ProstACT Global Phase 3 study's Part 2 in the U.S., marking a significant milestone for TLX591-Tx in treating metastatic castration-resistant prostate cancer.
- Clinical Protocol Alignment: The FDA and Telix achieved alignment on the clinical trial protocol, statistical analysis plan, and ongoing safety monitoring for Part 2, ensuring a consistent framework for study execution that lays the groundwork for international recruitment and expansion into the U.S.
- Ongoing Patient Recruitment: Part 2 continues to recruit patients in regions where regulatory approval has been granted, with an overall target enrollment of approximately 490 patients, demonstrating Telix's strong recruitment capabilities globally and enhancing its competitive position in the market.
- Enhanced Treatment Flexibility: The TLX591-Tx treatment regimen is completed over two weeks, allowing physicians to integrate it flexibly into existing treatment plans, minimizing disruption to future treatment options for patients, and showcasing its potential transformative impact in clinical practice.
See More
Telix Hosts Webinar on Neurologic Oncology Needs
- Webinar Announcement: Telix has scheduled a webinar addressing unmet needs in neurologic oncology, specifically glioma and glioblastoma, set for June 29, 2026, at 5:00 PM EDT, aiming to raise industry awareness through education.
- Clinical Update Presentation: Dr. David N. Cade, Telix's Chief Medical Officer, will provide a clinical update, followed by a fireside chat with medical experts from the Netherlands and Austria, showcasing the company's expertise and collaborative potential in neuro-oncology.
- Participant Engagement: The webinar will conclude with a Q&A session, allowing participants to directly engage with Dr. Cade and Telix CEO Richard Valeix, enhancing interaction with industry leaders and boosting the company's visibility among investors and healthcare professionals.
- Global Business Expansion: As a global biopharmaceutical company focused on developing radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases, this webinar will further solidify Telix's influence in international markets.
See More
Telix Pharmaceuticals and United Imaging Sign Strategic Collaboration MOU
- Strategic Collaboration Agreement: Telix Pharmaceuticals and United Imaging Healthcare have signed a Memorandum of Understanding in the U.S. to evaluate a strategic research collaboration aimed at advancing integrated theranostics solutions, fostering innovation in medical technology.
- Focus on Molecular Imaging: The partnership will initially assess Telix's molecular imaging portfolio and validated clinical protocols in conjunction with United Imaging's advanced scanner platforms, enhancing the efficiency of imaging diagnostics and treatment.
- Product Development Outlook: The collaboration will initially focus on TLX101-Px (Pixclara), a PET imaging candidate that has received FDA Fast Track and Orphan Drug designations, with a New Drug Application decision expected on September 11, 2026.
- Market Expansion Potential: This collaboration not only aids in product development within the U.S. market but also has the potential to expand into additional markets, further driving Telix's market share in the biopharmaceutical sector.
See More
Telix's TLX591-Tx Shows Promising Results in Prostate Cancer Trials
- Safety and Tolerability: Among 36 patients treated with TLX591-Tx, all received both doses per protocol with no new safety signals identified, where the most common adverse events were fatigue (53%) and nausea (28%), indicating good tolerability alongside standard treatments.
- Dosimetry and Pharmacokinetics: Radiation exposure to key organs was well below safety limits, with the highest absorbed dose in the liver ranging from 1.62 to 5.08 mGy/MBq, ensuring patient safety during treatment.
- Clinical Trial Progress: Part 2 of the randomized treatment expansion has commenced in jurisdictions with regulatory approval, targeting approximately 490 patients to further validate the efficacy of TLX591-Tx in combination with standard care.
- Market Potential: Telix's Chief Medical Officer noted that despite significant advances in clinical practice, mCRPC patients urgently need new treatment options, and the positive results from TLX591-Tx may introduce a new therapeutic avenue in this field.
See More
Telix Completes Patient Enrollment for TLX101-Tx Clinical Trial
- Patient Enrollment Completed: Telix Pharmaceuticals announced the completion of patient enrollment for the IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) in newly diagnosed glioblastoma patients, marking a significant milestone in the drug's development.
- Safety of Maximum Dose Confirmed: The study reached a maximum administered dose of 10GBq without any dose-limiting toxicities (DLTs) observed, providing strong support for the continued development of TLX101-Tx as a potential treatment for glioblastoma.
- Multicenter Study Design: The IPAX-2 study is an international, multicenter, open-label Phase 1 dose-finding study involving four sites across Australia, Austria, and the Netherlands, enrolling 12 patients to assess the safety and tolerability of TLX101-Tx in combination with standard treatment.
- Follow-up Clinical Trial Plans: TLX101-Tx is also under evaluation in the IPAX BrIGHT trial, assessing its combination with chemotherapy (lomustine), which is expected to be the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, further advancing its clinical application.
See More
Telix Pharmaceuticals Aligns with FDA to Advance Clinical Trial
- Clinical Trial Advancement: Telix Pharmaceuticals announced alignment with the FDA, allowing its TLX591-Tx to progress to Phase 2 of the ProstACT global trial for metastatic castration-resistant prostate cancer, marking a significant milestone in drug development.
- Trial Design Confirmation: The FDA confirmed that the safety data from Part 1 of the ProstACT trial is sufficient to support the progression of Part 2, while also aligning with Telix on the clinical trial protocol, statistical analysis plan, and ongoing safety monitoring, ensuring scientific rigor and safety.
- Revenue Growth Expectations: Telix expects Q1 2026 revenue to reach $230 million, a 24% increase year-over-year, and projects full-year revenue between $950 million and $970 million, indicating strong growth potential in the biopharmaceutical sector.
- Stock Performance Review: TLX shares have traded between $6.28 and $16.98 over the past year, closing at $11.84, up 2.69% from the previous day, reflecting market optimism regarding the company's future developments.
See More
Telix and FDA Align on Advancing ProstACT Study into Part 2
- FDA Approval Progress: Telix successfully held a Type B meeting with the FDA, which confirmed that the safety data from Part 1 is sufficient to support the advancement of the ProstACT Global Phase 3 study's Part 2 in the U.S., marking a significant milestone for TLX591-Tx in treating metastatic castration-resistant prostate cancer.
- Clinical Protocol Alignment: The FDA and Telix achieved alignment on the clinical trial protocol, statistical analysis plan, and ongoing safety monitoring for Part 2, ensuring a consistent framework for study execution that lays the groundwork for international recruitment and expansion into the U.S.
- Ongoing Patient Recruitment: Part 2 continues to recruit patients in regions where regulatory approval has been granted, with an overall target enrollment of approximately 490 patients, demonstrating Telix's strong recruitment capabilities globally and enhancing its competitive position in the market.
- Enhanced Treatment Flexibility: The TLX591-Tx treatment regimen is completed over two weeks, allowing physicians to integrate it flexibly into existing treatment plans, minimizing disruption to future treatment options for patients, and showcasing its potential transformative impact in clinical practice.
See More
Telix Hosts Webinar on Neurologic Oncology Needs
- Webinar Announcement: Telix has scheduled a webinar addressing unmet needs in neurologic oncology, specifically glioma and glioblastoma, set for June 29, 2026, at 5:00 PM EDT, aiming to raise industry awareness through education.
- Clinical Update Presentation: Dr. David N. Cade, Telix's Chief Medical Officer, will provide a clinical update, followed by a fireside chat with medical experts from the Netherlands and Austria, showcasing the company's expertise and collaborative potential in neuro-oncology.
- Participant Engagement: The webinar will conclude with a Q&A session, allowing participants to directly engage with Dr. Cade and Telix CEO Richard Valeix, enhancing interaction with industry leaders and boosting the company's visibility among investors and healthcare professionals.
- Global Business Expansion: As a global biopharmaceutical company focused on developing radiopharmaceuticals to address significant unmet medical needs in oncology and rare diseases, this webinar will further solidify Telix's influence in international markets.
See More
Telix Pharmaceuticals and United Imaging Sign Strategic Collaboration MOU
- Strategic Collaboration Agreement: Telix Pharmaceuticals and United Imaging Healthcare have signed a Memorandum of Understanding in the U.S. to evaluate a strategic research collaboration aimed at advancing integrated theranostics solutions, fostering innovation in medical technology.
- Focus on Molecular Imaging: The partnership will initially assess Telix's molecular imaging portfolio and validated clinical protocols in conjunction with United Imaging's advanced scanner platforms, enhancing the efficiency of imaging diagnostics and treatment.
- Product Development Outlook: The collaboration will initially focus on TLX101-Px (Pixclara), a PET imaging candidate that has received FDA Fast Track and Orphan Drug designations, with a New Drug Application decision expected on September 11, 2026.
- Market Expansion Potential: This collaboration not only aids in product development within the U.S. market but also has the potential to expand into additional markets, further driving Telix's market share in the biopharmaceutical sector.
See More
Telix's TLX591-Tx Shows Promising Results in Prostate Cancer Trials
- Safety and Tolerability: Among 36 patients treated with TLX591-Tx, all received both doses per protocol with no new safety signals identified, where the most common adverse events were fatigue (53%) and nausea (28%), indicating good tolerability alongside standard treatments.
- Dosimetry and Pharmacokinetics: Radiation exposure to key organs was well below safety limits, with the highest absorbed dose in the liver ranging from 1.62 to 5.08 mGy/MBq, ensuring patient safety during treatment.
- Clinical Trial Progress: Part 2 of the randomized treatment expansion has commenced in jurisdictions with regulatory approval, targeting approximately 490 patients to further validate the efficacy of TLX591-Tx in combination with standard care.
- Market Potential: Telix's Chief Medical Officer noted that despite significant advances in clinical practice, mCRPC patients urgently need new treatment options, and the positive results from TLX591-Tx may introduce a new therapeutic avenue in this field.
See More
Telix Completes Patient Enrollment for TLX101-Tx Clinical Trial
- Patient Enrollment Completed: Telix Pharmaceuticals announced the completion of patient enrollment for the IPAX-2 study of TLX101-Tx (¹³¹I-iodofalan) in newly diagnosed glioblastoma patients, marking a significant milestone in the drug's development.
- Safety of Maximum Dose Confirmed: The study reached a maximum administered dose of 10GBq without any dose-limiting toxicities (DLTs) observed, providing strong support for the continued development of TLX101-Tx as a potential treatment for glioblastoma.
- Multicenter Study Design: The IPAX-2 study is an international, multicenter, open-label Phase 1 dose-finding study involving four sites across Australia, Austria, and the Netherlands, enrolling 12 patients to assess the safety and tolerability of TLX101-Tx in combination with standard treatment.
- Follow-up Clinical Trial Plans: TLX101-Tx is also under evaluation in the IPAX BrIGHT trial, assessing its combination with chemotherapy (lomustine), which is expected to be the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, further advancing its clinical application.
See More
